Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Liraglutide gives adolescents with obesity an edge in managing weight loss

Key clinical point: Liraglutide plus lifestyle therapy in adolescents with obesity led to greater reductions in BMI, compared with lifestyle therapy alone.

Major finding: Participants in the liraglutide group also saw a greater reduction in BMI compared with those in the placebo group (estimated difference, 4.64 percentage points).

Study details: A 56-week, randomized, controlled, double-blind trial with 251 adolescents (aged 12-17 years) with obesity.

Disclosures: Several of the authors reported that they are employees of Novo Nordisk, which funded the research.

Citation:

Kelly AS et al. N Engl J Med. 2020 Mar 31. doi: 10.1056/NEJMoa1916038.